Slide 1: Earnings Call – Q2 - FY25
Earnings Call – Q2 - FY25 April 3, 2025 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Except for historical information, the matters discussed in this presentation are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate” and similar expressions (as well as other words or expressions referenc
Slide 3: Second Quarter Highlights
Second Quarter Highlights CURRENT PERIOD $22.4M +23% $0.15 $0.31 29% Revenue Revenue Diluted EPS Adj. Adj. EBITDA Growth Diluted EPS Margin Prior Year Comparison (2Q24) $18.3M +16% $0.20 $0.32 39% Revenue Revenue Diluted EPS Adj. Adj. EBITDA Growth Diluted EPS Margin 3
Slide 4: Trailing Twelve Months (TTM) 2Q25 Highlights
Trailing Twelve Months (TTM) 2Q25 Highlights CURRENT PERIOD $78.6M +21% $0.36 $0.93 26% Revenue Revenue Diluted EPS Adj. Adj. EBITDA Growth Diluted EPS Margin Prior Year Comparison (2Q24) $64.7M +19% $0.52 $1.09 34% Revenue Revenue Growth Diluted EPS Adj. Adj. EBITDA Diluted EPS Margin 4
Slide 5: Software Highlights
Software Highlights – Overall software revenue growth of 16% for 2Q25 and 18% for TTM General – – Good renewal rate, upsell and new logo activity Revenue contribution from ALI and MC in-line with expectations Cheminformatics Physiologically Clinical Quantitative Adaptive Learning & Medical (CHEM) Ba
Slide 6: Services Highlights
Services Highlights – Overall services revenue growth of 34% for 2Q25 and 28% for TTM General – – Total backlog $20.4M, over 94% expected to be converted to revenue within 12 months Revenue contribution from MC in-line with expectations Clinical Physiologically Physiologically Clinical Quantitative
Slide 7: Financial Results
Financial Results
Slide 8: Revenue - Q2
Revenue - Q2 (in millions) 2Q25 Mix +23% +16% +34% Total Revenue Software Revenue Services Revenue Growth Growth Growth 2Q24 Mix 8
Slide 9: Revenue - YTD
Revenue - YTD (in millions) FY25 Mix +26% +26% +26% Total Revenue Software Revenue Services Revenue Growth Growth Growth FY24 Mix 9
Slide 10: Revenue - Trailing Twelve Months (TTM)
Revenue - Trailing Twelve Months (TTM) (in millions) 2Q25 Mix +21% +18% +28% Total Revenue Software Revenue Services Revenue Growth Growth Growth 2Q24 Mix 10
Slide 11: Software Solutions as % of Software Revenue
Software Solutions as % of Software Revenue 2Q25 TTM Second Quarter Highlights GastroPlus® ▪ 7 new customers ▪ 7 upsells to existing customers MonolixSuite ▪ 11 new customers ▪ 2 upsells to existing customers ADMET Predictor® ▪ 10 new customers ▪ 7 upsells to existing customers QSP ▪ Added model lic
Slide 12: Software Performance Metrics - Q2
Software Performance Metrics - Q2 Commercial Customers Avg. Revenue per Customer Renewal Rates (in thousands) 12
Slide 13: Software Performance Metrics - TTM
Software Performance Metrics - TTM Commercial Customers Avg. Revenue per Customer Renewal Rates (in thousands) 13
Slide 14: Services Solutions as % of Services Revenue
Services Solutions as % of Services Revenue 2Q25 TTM 14
Slide 15: Services Performance Metrics
Services Performance Metrics Total Projects Backlog (in millions) 15
Slide 16: Income Statement Summary - Q2 FY25
Income Statement Summary - Q2 FY25 (1) (in millions, except Diluted EPS and Adjusted Diluted EPS) 2Q25 % of Rev 2Q24 % of Rev Revenue $22.4 100% $18.3 100% Cost of revenue 9.3 41% 5.1 28% Gross profit 13.1 59% 13.2 72% R&D 2.1 10% 1.3 7% S&M 3.7 17% 1.9 11% G&A 4.6 20% 5.5 30% Total operating exp 10
Slide 17: Income Statement Summary - YTD
Income Statement Summary - YTD (in millions, except Diluted EPS and Adjusted Diluted EPS) FY25 % of Rev FY24 % of Rev Revenue $41.4 100% $32.8 100% Revenue growth 26% 18% Gross profit 23.3 56% 23.1 70% R&D 4.0 10% 2.5 8% S&M 6.6 16% 3.9 12% G&A 9.9 24% 11.2 34% Total operating exp 20.5 50% 17.7 54%
Slide 18: Balance Sheet Summary
Balance Sheet Summary (in millions) February 28, 2025 August 31, 2024 Cash and short-term investments $21.4 $20.3 Total current assets 46.7 39.3 Total assets $201.4 $196.6 Current liabilities 10.7 12.1 Long-term liabilities 1.2 2.1 Total liabilities 11.9 14.2 Shareholders’ equity 189.5 182.4 Total l
Slide 19: Fiscal 2025 Guidance
Fiscal 2025 Guidance Guidance Total Revenue $90M - $93M Total Revenue Growth 28% - 33% Software Revenue Mix 55% - 60% Adjusted EBITDA(1) Margin 31% - 33% Adjusted Diluted EPS(2) $1.07 - $1.20 (1) Adjusted EBITDA represents net income excluding the effect of interest expense (income), provision (bene
Slide 20: Conclusion
Conclusion CONTINUED LEADERSHIP POSITION IN LIFE SCIENCES TECHNOLOGY MARKET Delivering on our Developing organization to Expanding our software and commitment to scientific Creating shareholder value drive growth services portfolio leadership • Release of GastroPlus X • Optimization of business • AL
Slide 21: Adjusted EBITDA Non-GAAP Reconciliation
Adjusted EBITDA Non-GAAP Reconciliation (1) (in millions) FY24 FY25 FY24 FY25 Q1 Q2 Q3 Q4 Q1 Q2 Full Year YTD Net Income $1.945 $4.029 $3.137 $0.843 $0.206 $3.074 $9.954 $3.280 Excluding: Interest income and expense, net (1.292) (1.348) (1.522) (0.213) (0.159) (0.154) (4.375) (0.313) Provision for i
Slide 22: Adjusted Diluted EPS Non-GAAP Reconciliation
Adjusted Diluted EPS Non-GAAP Reconciliation (1) (in millions, except Diluted EPS and Adjusted Diluted EPS) FY24 FY25 FY24 FY25 Q1 Q2 Q3 Q4 Q1 Q2 Full Year YTD Net Income (GAAP) $1.945 $4.029 $3.137 $0.843 $0.206 $3.074 $9.954 $3.280 Excluding: Amortization 0.991 0.991 1.122 2.059 2.130 2.130 5.163
Slide 23: Investor Relations Contact
Investor Relations Contact: Lisa Fortuna Financial Profiles 310-622-8251 slp@finprofiles.com